Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100 - Atezolizumab 1200 Maintenance, Non-Small Cell Lung Carcinoma

Protocol-ID: 1272 V1.0 (Short), ATEZ1200/CRBP6/NPAC100 - ATEZ1200 maint., NSCLC

Indication(s)

Lung Carcinoma, Non-Small Cell (non-squamous); ICD-10 C34.-

Protocol classification

Classification: alternative
Intensity: Standard dose
Therapy mode: First line
Therapy intention: palliative

Cycles

Cycle length 21 days, recommended cycles: 10

Protocol sequences

IMpower130: ATEZ1200/CRBP6/NPAC100, NSCLC (PID1238) -|- ATEZ1200/CRBP6/NPAC100 - ATEZ1200 maint. (PID1272)

Risks

Emetogenicity (MASCC/ESMO): high (>90%)
Neutropenia: high (21-40%) °3-4: 32%
Thrombocytopenia below 50 000/µl: very high (>41%) °3-4: 45%
Anemia Hb below 8g/dl: high (16-30%) °3-4: 29%
Diarrhea: CTC AE °3-4: 5%
Fatigue: CTC AE °3-4: 6%
Nausea: CTC AE °3-4: 3%

Therapy

Day	Substance	Dosage	Appl.	Inf. time	Procedure
HYD Hydration: Balanced Crystalloid Solution
Access: peripheral venous
Hydration before, during, or after antitumor therapy
1	Balanced Crystalloid Solution	500 ml	i.v.	60 min	60 min before Atezolizumab (d1)

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
CTX Medical tumor therapy: ATEZ1200
Access: peripheral venous
Atezolizumab in non-small cell, non-plate epithelial lung cancer
1	Atezolizumab	1200 mg	NaCl 0.9% 250 ml	i.v.	60 min	Sequence

References

West H, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol 2019 May 20; [PMID]

Recommendations

01/2023: European Society for Medical Oncology
02/2024: National Comprehensive Cancer Network

The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 26.06.2019